Skip to content

THE SCIENCE NOTES

Complex Science, Simplified.

  • Cell and Molecular Biology
  • Protocols and Techniques
  • Food Science
  • Microbiology
  • Biotechnology
  • Biochemistry
  • Bacteriology
  • Anatomy and Physiology
  • Immunology
  • Cancer
  • Biology
  • News & Blogs
  • Contact Us
  • Privacy Policy
THE SCIENCE NOTES
  • Cell and Molecular Biology
  • Protocols and Techniques
  • Food Science
  • Microbiology
  • Biotechnology
  • Biochemistry
  • Bacteriology
  • Anatomy and Physiology
  • Immunology
  • Cancer
  • Biology
  • News & Blogs
  • Contact Us
  • Privacy Policy

Category: Cancer

Infographic illustrating Mosunetuzumab as a bispecific CD20/CD3 antibody, showing T-cell engagement, B-cell targeting, mechanism of action, approvals timeline, and key facts about its use in follicular lymphoma, created by www.thesciencenotes.com
Posted on March 23, 2026 Cancer

Mosunetuzumab (Lunsumio): Mechanism, Pharmacology, Uses & Side Effects

Explore a detailed guide on Mosunetuzumab, including mechanism, pharmacology, clinical use, safety, and FDA approval for follicular lymphoma. Read more

Infographic showing the mechanism of action of Teclistamab where the bispecific antibody binds BCMA on myeloma cells and CD3 on T cells to activate cytotoxic T-cell signaling and tumor cell killing.
Posted on March 12, 2026March 24, 2026 Cancer Immunology

Teclistamab in Multiple Myeloma: Mechanism, Structure and Clinical Trial Results

Teclistamab is a BCMA × CD3 bispecific antibody that redirects T cells to kill multiple myeloma cells in relapsed patients. Read more

Infographic showing BCMA-targeted therapies for multiple myeloma including bispecific antibody teclistamab, CAR-T cell therapy, and antibody-drug conjugate belantamab mafodotin.
Posted on March 12, 2026March 24, 2026 Cancer Immunology

BCMA-Targeted Therapies in Multiple Myeloma: Teclistamab vs CAR-T vs Antibody-Drug Conjugates

Compare BCMA therapies in multiple myeloma including Teclistamab, CAR-T therapy, and antibody-drug conjugates with mechanisms and clinical outcomes. Read more

BCMA signaling pathway cartoon diagram showing NF-κB, PI3K-AKT, and MAPK pathways activated by BCMA in multiple myeloma cells
Posted on March 12, 2026March 24, 2026 Cancer Immunology

BCMA Signaling Pathway in Multiple Myeloma: Structure, Function and Therapeutic Targeting

BCMA signaling drives plasma cell survival in multiple myeloma through BAFF/APRIL activation of NF-κB, PI3K-AKT, and MAPK pathways. Read more

A scientific table comparing five bispecific antibodies. The top rows show structural designs: a BiTE (Blinatumomab) and four IgG-like structures (Mosunetuzumab, Epcoritamab, Glofitamab, and Odronextamab). The bottom panel illustrates "Mechanism & Pharmacokinetics," showing tissue penetration, T-cell engagement levels, and PK curves for each molecule.
Posted on March 12, 2026April 3, 2026 Cancer Immunology

Bispecific Antibodies in Cancer Immunotherapy

Explore the structural design, mechanism of action, and clinical applications of bispecific antibodies in cancer immunotherapy for targeted tumor killing. Read more

Posted on March 11, 2026March 24, 2026 Cancer

p53 Structure, Regulation, and Role in Cancer

Comprehensive review of p53 structure, regulation, activation pathways, and its role in cancer, including mechanisms of mutation and therapeutic targeting. Read more

A scientific infographic titled "9 Hallmarks of Cancer." The image features a central circular diagram of a tumor microenvironment with blood vessels and immune cells, surrounded by nine colorful teardrop-shaped sections. Each section explains a hallmark, such as "Proliferative Signaling" or "Immune Evasion," listing associated genes like KRAS, TP53, and VEGF. The bottom includes a "Systemic Interactions" bar and the credit "www.thesciencenotes.com."
Posted on February 5, 2026February 5, 2026 Cancer

Hallmarks of Cancer: How Tumors Grow, Spread, and Resist Treatment

Comprehensive guide on cancer hallmarks, tumor microenvironment, systemic effects, and therapeutic strategies for students. Read more

Illustration of Blinatumomab Mechanism
Posted on January 26, 2026 Cancer

Blinatumomab in B-ALL: BiTE Structure, Mechanism, Resistance & Trials

Blinatumomab is a first-in-class BiTE immunotherapy for B-ALL. Explore its molecular structure, T-cell redirection mechanism, resistance pathways, and clinical trials. Read more

Acute Lymphoblastic Leukemia
Posted on July 19, 2025July 19, 2025 Cancer Immunology

Acute Lymphoblastic Leukemia (ALL) Treatment: A Scientific Overview

Effective treatments for Acute Lymphoblastic Leukemia (ALL), including chemotherapy, CAR T-cell therapy, and stem cell transplant. Read more

CAR-T Vector Plasmid Structure — www.sciencenotes.com
Posted on June 27, 2025June 27, 2025 Cancer Immunology

Structural Components of a CAR-T Vector Plasmid: A Comprehensive Overview

A CAR-T vector plasmid encodes the engineered receptor that enables T cells to target cancer. It includes key elements for antigen recognition, cell signaling, and controlled gene expression. Read more

Posts pagination

1 2 3 →

Recent Posts

  • Type 2 Diabetes: Symptoms, Diagnosis, and Management Guide
  • Type 1 Diabetes: A Complete Guide to Causes, Symptoms, and Treatment
  • Varicoceles: Symptoms, Causes, and Infertility Treatment
  • What is Syphilis? A Guide to Symptoms, Testing, and Penicillin
  • What is Dengue Fever? Symptoms, Treatment, and Prevention Guide
No comments to show.
© 2026 THE SCIENCE NOTES / Powered by WordPress / Theme by Design Lab